T2 Biosystems, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2022-11-25: Form 8-K; Period of report 2022-11-22; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2022-11-10: Form 8-K; Period of report 2022-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2022-11-07: Form 8-K; Period of report 2022-10-20; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 5.02.
- 2022-10-14: Form 8-K; Period of report 2022-10-14; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2022-11-25 | 8-K | 2022-11-22 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On November 22, 2022, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (“MVLS”) had been below the $35 million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). | d396110d8k.htm |
| 2022-11-10 | 8-K | 2022-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2022, the Company issued a press release announcing its financial results for its fiscal quarter ended September 30, 2022, and held a conference call to discuss those results. | d387879d8k.htm |
| 2022-11-07 | 8-K | 2022-10-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 5.02 On November 1, 2022, Alec Barclay notified T2 Biosystems, Inc. (the “Company”) of his resignation as Chief Operations Officer of the Company, effective as of November 30, 2022. 7.01 On November 7, 2022, the Company issued a press release announcing the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation (“Cohen Foundation”) have selected T2 Biosystems as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator (“LymeX”) prize competition to accelerate the development of Lyme disease diagnostics. 8.01 On October 20, 2022, the Company issued a press release announcing that it has initiated studies to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii. | d143675d8k.htm |
| 2022-10-14 | 8-K | 2022-10-14 | 7.01 Regulation FD Disclosure | 7.01 On October 14, 2022, the Company issued a press release announcing the publication of three new, peer-reviewed studies. | d409720d8k.htm |
| 2022-10-13 | 8-K | 2022-10-13 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On October 13, 2022, the Company issued a press release announcing plans to develop and commercialize a rapid molecular diagnostic test for detection of early Lyme disease. 8.01 On October 13, 2022, the Company issued a press release announcing plans to develop and commercialize a rapid molecular diagnostic test for detection of early Lyme disease. | d394750d8k.htm |
| 2022-10-12 | 8-K | 2022-10-12 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.03 To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. 5.03 On October 11, 2022, T2 Biosystems, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”), at which the Company’s stockholders voted to approve an amendment to the Company’s restated certificate of incorporation (the “Certificate of Incorporation”) to effect a reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a reverse split ratio ranging from any whole number between and including 1-for-10 and 1-for-50, with the exact ratio to be determined at the discretion of the Board of Directors of the Company (the “Board”). | d409744d8k.htm |
| 2022-10-12 | 8-K | 2022-10-11 | 2.02 Results of Operations and Financial Condition; 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 On October 12, 2022, T2 Biosystems, Inc. (the “Company”) issued a press release announcing preliminary estimated financial results for the quarter ended September 30, 2022. 5.07 On October 11, 2022, the Company held its annual meeting of stockholders (the “Annual Meeting”). 7.01 On October 12, 2022, the Company issued a press release announcing the Reverse Stock Split. 8.01 • Estimated third quarter total revenue is expected to be approximately $3.7 million, including estimated product revenue of approximately $2.6 million. | d283495d8k.htm |
| 2022-09-30 | 8-K | 2022-09-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d371393d8k.htm |
| 2022-09-30 | 8-K | 2022-09-26 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d407448d8k.htm |
| 2022-08-30 | 8-K | 2022-08-24 | 8.01 Other Events | 8.01 On August 24, 2022, T2 Biosystems, Inc. (the “Company”) received written notice (the “Compliance Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(b)(2) (“Rule 5550(b)(2)”) which requires that companies listed on the Nasdaq Capital Market maintain a minimum Market Value of Listed Securities, as defined by Nasdaq (“MVLS”), of $35 million or greater. | d746253d8k.htm |
| 2022-08-17 | 8-K | 2022-08-15 | 2.02 Results of Operations and Financial Condition | 2.02 On August 15, 2022, the Company issued a press release announcing its financial results for its fiscal quarter ended June 30, 2022, and held a conference call to discuss those results. | d294268d8k.htm |
| 2022-08-09 | 8-K | 2022-08-09 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On August 9, 2022, the Company issued a press release announcing plans to explore the potential to develop a rapid molecular diagnostic test for detection of the monkeypox virus, including technical and commercial feasibility.. 8.01 On August 9, 2022, the Company issued a press release announcing plans to explore the potential to develop a rapid molecular diagnostic test for detection of the monkeypox virus, including technical and commercial feasibility. | d310015d8k.htm |
| 2022-07-25 | 8-K | 2022-07-22 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On July 22, 2022, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty-five consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (“MVLS”) had been below the $35 million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). | d577417d8k.htm |
| 2022-07-11 | 8-K | 2022-07-08 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On July 11, 2022, the Company issued a press release announcing that the FDA had informed the Company that its application for Breakthrough Device Designation for the T2Lyme Panel had been granted. 8.01 On July 11, 2022, the Company issued a press release announcing that the FDA had informed the Company that its application for Breakthrough Device Designation for the T2Lyme Panel had been granted. | d663956d8k.htm |
| 2022-07-06 | 8-K | 2022-06-30 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 3.03 On June 30, 2022, the Board of Directors of T2 Biosystems, Inc. (the “Company”) approved and adopted an amendment to Article II, Section 2.8 of the Company’s Amended and Restated Bylaws to lower the quorum required for the transaction of business at all meetings of stockholders from the holders of a majority in voting power of the capital stock issued and outstanding and entitled to vote to the holders of at least one-third in voting power of the common stock issued and outstanding and entitled to vote (the “By-laws Amendment”). 5.03 The description of the By-laws Amendment in Item 3.03 is incorporated herein by reference. 8.01 • Preliminary unaudited second quarter 2022 total revenue is expected to be $5.8 to $6.1 million, including product revenue of $2.5 to $2.7 million and research revenue of $3.3 to $3.4 million. | d370202d8k.htm |
| 2022-06-10 | 8-K | 2022-06-09 | 8.01 Other Events | 8.01 As previously disclosed, on May 5, 2022 T2 Biosystems, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company had failed to maintain compliance with the minimum bid requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). | d367290d8k.htm |
| 2022-05-24 | 8-K | 2022-05-23 | 8.01 Other Events | 8.01 On April 26, 2022, the Company issued a press release announcing it had submitted an application with the FDA for Breakthrough Device Designation for the Company’s T2Biothreat™ Panel. | d363716d8k.htm |
| 2022-05-11 | 8-K | 2022-05-05 | 2.02 Results of Operations and Financial Condition; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 2.02 On May 5, 2022, the Company issued a press release announcing its financial results for its fiscal quarter ended March 31, 2022, and held a conference call to discuss those results. 3.01 On November 5, 2021, we received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Market. | d329066d8k.htm |
| 2022-04-27 | 8-K | 2022-04-27 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On April 27, 2022, T2 Biosystems, Inc. (the “Company”) issued a press release announcing it has submitted an application with the U.S. Food and Drug Administration for Breakthrough Device Designation for the Company’s T2Biothreat™ Panel. 8.01 On April 27, 2022, the Company announced that it submitted an application with the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for the Company’s T2Biothreat™ Panel. | d352906d8k.htm |
| 2022-04-12 | 8-K | 2022-04-12 | 7.01 Regulation FD Disclosure | 7.01 On April 12, 2022, T2 Biosystems, Inc. (the “Company”) hosted a virtual analyst and investor meeting and made available on its website the presentation materials attached as Exhibit 99.1 to this Current Report on Form 8-K to be presented during the meeting. | d342457d8k.htm |
| 2022-04-01 | 8-K/A | 2022-03-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d282501d8ka.htm |
| 2022-04-01 | 8-K | 2022-03-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d330903d8k.htm |
| 2022-02-17 | 8-K | 2022-02-15 | 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.02 On February 17, 2022, the Company issued a press release announcing its financial results for its fiscal quarter and full year ended December 31, 2021, and held a conference call to discuss those results. | d275483d8k.htm |
| 2022-01-11 | 8-K | 2022-01-11 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On January 11, 2022, T2 Biosystems, Inc. (the “Company”) issued a press release announcing preliminary estimated financial results for its fiscal quarter and full year ended December 31, 2021. 8.01 • Achieved full year 2021 total revenue of $27.7 million, including product revenue of $16.7 million, representing an increase of 53% and 43%, respectively, compared to the prior year. | d139907d8k.htm |